Elite Pharmaceuticals Inc's Form 4 filing
Elite Pharmaceuticals IncELTP · filed Aug 26, 2025
- Accession no.
- 0001493152-25-012347
- Filed
- Aug 26, 2025, 5:17 PM ET
- Trade date
- Aug 22-25, 2025
- Filing delay
- 4 days
- Rule 10b5-1 plan
- Not checked
This filing lists 2 non-derivative transactions and 1 derivative transaction. Open-market sales total $262.1K. It was filed 4 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Elite Pharmaceuticals IncCIK 0001053369 | Officer (EVP Operations) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Aug 22, 2025 | Common Stock | SSaleDisposed | −500,000 | $0.5243F1 | −$262,150 | 1,800,000 | Direct | |
| Aug 25, 2025 | Common Stock | MOption exerciseAcquired | +2,500,000 | $0.03 | +$75,000 | 4,300,000 | Direct |
Derivative securities (Table II)
Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.
| Trade date | Security | Transaction | Underlying shares | Unit price | Value | Held after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Aug 25, 2025 | Common Stock | MOption exerciseDisposed | −2,500,000 | $0.00 | $0 | 2,500,000 | Direct |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F1
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.52 to $0.56, inclusive. The reporting person undertakes to provide to Elite Phannaceuticals, any security holder of Elite Pharmaceuticals, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote(1) to this Form 4
Referenced by the price of 1 transaction in Table I.